ArticleInternational journal of particle therapy2026
Dosimetric Comparison Between Brass Aperture-Enhanced Proton Pencil Beam Scanning and Photon Stereotactic Radiosurgery for Cerebral Arteriovenous Malformations.
Article in International journal of particle therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The current study aimed to quantify potential dosimetric advantages of a novel, brass aperture-enhanced, proton-based stereotactic radiosurgery (SRS) technique compared to conventional photon linac-based SRS in patients with cerebral arteriovenous malformations (AVMs). Materials and Methods: A retrospective review was performed of patients treated with proton SRS for cerebral AVMs at our institution between 2023 and 2025. Volumetric modulated arc therapy linac-based SRS plans were generated for dosimetric comparison and normalized to match the clinical target volume (CTV) prescription coverage of the delivered proton plan. SRS plan quality was evaluated by Radiation Therapy Oncology Group conformity and homogeneity indices (CI, HI). The V12 Gy representing the normal brain volume receiving ≥ 12 Gy including the CTV (total brain) was measured. Results: Fourteen patients were included, and most had no prior hemorrhage (64%), embolization (79%), or AVM-directed radiotherapy (86%). Three patients received staged radiation, totaling 17 treatment plans for review. Mean AVM size was 8.8 cc (0.4-30.6). SRS dose ranged from 17 to 20 Gy with 3 larger AVMs treated using volumetric staging. For the 4 AVMs ≤2.0 cc in size, the average CI was 1.89 and 1.81 for photons and protons, respectively. The average CI for AVMs >2 cc was 1.15 and 1.17 for photons and protons, respectively. A statistically significant difference was observed with HI ( Conclusion: Brass aperture-enhanced proton PBS SRS improved V12 Gy in 15 of 17 plans (88.2%), including small volume AVMs and AVMs close to the brainstem. These findings are hypothesis-generating and must be interpreted cautiously. Maturation of our clinical outcome data (AVM obliteration and symptomatic radionecrosis rates) will yield further insights.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.